Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Uterine Cervical Neoplasms 2Uterine Cervical Dysplasia 1Precancerous Conditions 1Oropharyngeal Neoplasms 1

Interventions

Cisplatin 57Radiotherapy 35Radiotherapy, Intensity-Modulated 30Magnetic Resonance Spectroscopy 24Radiation 21Carboplatin 19pembrolizumab 18Specimen Handling 16Platinum 14Cetuximab 141,2-diaminocyclohexaneplatinum II citrate 14Surveys and Questionnaires 13Paclitaxel 13Biopsy 11Surgical Procedures, Operative 10Fluorouracil 10Docetaxel 9Taxes 8Nivolumab 8Drug Therapy 8Chemoradiotherapy 8durvalumab 7Fluorodeoxyglucose F18 7Observation 6Blood Specimen Collection 6fludarabine 5X-Rays 5Immunohistochemistry 5Cyclophosphamide 5aldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oropharyngeal Neoplasms × human papillomavirus vaccine, TA × Clear all
NCT05799144 2025-10-22

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
54 enrolled
Head & Neck

Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡